Bacil Pharma Ltd

Bacil Pharma Partnership

Bacil Pharma's wholly owned subsidiary signed an R&D agreement with Efdee Pharma for pharmaceutical products. The estimated project cost is Rs. 35 Crore.

Value

₹35.00 Cr

Bacil Pharma Other Announcement

Bacil Pharma Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026, in compliance with SEBI Regulation 31.

Bacil Pharma Q2 FY27 Results: Net Loss of ₹0.1 Cr

Bacil Pharma Ltd reported a net loss of ₹0.1 Cr for Q2 FY27.

Key figure

Net loss ₹0.1 Cr

Bacil Pharma Management Change

Mr. Dikshant Singh Panwar has resigned as Whole-Time Company Secretary and Compliance Officer of Bacil Pharma Limited, effective October 8, 2026.

Bacil Pharma Board Meeting Date

Bacil Pharma will hold a board meeting on October 14, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.